Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crop Life ScienceNSE:CLSL +4.64%75 Equity-to-Asset is 0.41 as of Mar. 2026, which is 2% above its 10-year median of 0.40. GuruFocus rates NSE:CLSL with a GF Score™ of 75/100 and a GF Value™ of ₹56.26 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 260 Agriculture companies, Crop Life Science ranks worse than 68.46% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Crop Life Science's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹842 Mil. Crop Life Science's Total Assets for the quarter that ended in Mar. 2026 was ₹2,080 Mil.
Therefore, Crop Life Science's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.41.
The historical rank and industry rank for Crop Life Science's Equity-to-Asset or its related term are showing as below:
NSE:CLSL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38 Med: 0.4 Max: 0.43
Current: 0.41
During the past 7 years, the highest Equity to Asset Ratio of Crop Life Science was 0.43. The lowest was 0.38. And the median was 0.40.
NSE:CLSL's Equity-to-Asset is ranked worse than 68.46% of 260
companies
in the Agriculture industry
Industry Median: 0.52
vs NSE:CLSL: 0.41
Crop Life Science (NSE:CLSL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Crop Life Science Equity-to-Asset Related Terms
Crop Life Science Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Crop Life Science's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CLSL vs CTVA, CF, MOS: Equity-to-Asset Comparison
For the Agricultural Inputs subindustry, Crop Life Science's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crop Life Science Equity-to-Asset vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Crop Life Science's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Crop Life Science's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Crop Life Science's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crop Life Science (NSE:CLSL) has a Equity-to-Asset of 0.41 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Crop Life Science and its competitors. This is near median its historical median of 0.40. Over the past decade, Crop Life Science's Equity-to-Asset has ranged from 0.38 to 0.43. According to the industry distribution chart, Crop Life Science ranks #178 out of 260 companies in the Agriculture industry, placing it in the top 68.5%.
Is Crop Life Science's Equity-to-Asset too high?
Crop Life Science's current Equity-to-Asset of 0.41 is near median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 0.43. The Agriculture industry median Equity-to-Asset is 0.52. Crop Life Science's value of 0.41 is 21.2% below this industry median. Based on the distribution chart, Crop Life Science ranks #178 out of 260 companies in the Agriculture industry, which is below the industry midpoint. Overall, Crop Life Science has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crop Life Science's Equity-to-Asset compare to CTVA and CF?
According to the Agriculture industry distribution chart, Crop Life Science ranks #178 out of 260 companies for Equity-to-Asset. This places Crop Life Science in the lower half of its industry. The industry median Equity-to-Asset is 0.52. Crop Life Science's value of 0.41 is 21.2% below this benchmark. Historically, Crop Life Science's own Equity-to-Asset has ranged from 0.38 to 0.43 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.52, Crop Life Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Agriculture company?
The median Equity-to-Asset among Agriculture companies is 0.52, based on 260 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crop Life Science's current Equity-to-Asset of 0.41 is 21.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Crop Life Science and its competitors. For the Agriculture industry, the median Equity-to-Asset is 0.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crop Life Science's current Equity-to-Asset is 0.41, which is near median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crop Life Science stock overvalued right now?
Based on GuruFocus' analysis, Crop Life Science (NSE:CLSL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹56.26, compared to a current price of ₹87.90 — trading 56.2% above its estimated fair value. The current Equity-to-Asset is 0.41, which is near median its 10-year median of 0.40 and 21.2% below the Agriculture industry median of 0.52. Crop Life Science's overall GF Score™ is 75/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Crop Life Science (NSE:CLSL), the current Equity-to-Asset is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crop Life Science (NSE:CLSL) Overvalued in 2026?
Based on GuruFocus' analysis, Crop Life Science stock appears to be overvalued.
The current stock price of ₹87.90 is trading 56.2% above its estimated GF Value™ of ₹56.26.
GuruFocus considers Crop Life Science to be Significantly Overvalued.
Key valuation signals for NSE:CLSL:
Equity-to-Asset: 0.41 (near median its 10-year median of 0.40)
GF Value™: ₹56.26 vs. price of ₹87.90 (56.2% above fair value)
Industry Position: 21.2% below the Agriculture median (#178 of 260)
No single metric tells the full story. See the NSE:CLSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crop Life Science Ltd manufactures and distributes a broad range of crop protection chemicals, including pesticides, insecticides, fungicides, herbicides, micro fertilizers, bio-pesticides, bio-fertilizers, plant growth regulators, and soil plant health products. The company operates its manufacturing facility in Ankleshwar, Gujarat, leveraging technology to maintain quality standards. It serves agricultural markets within India and exports to countries including Indonesia, Bangladesh, Egypt, Myanmar, Vietnam, and Sudan. Segments include Agro chemicals and Agro trade. Revenue is generated through the sale of its agricultural chemicals and related products to farmers, distributors, and agri-businesses.
75GF Score
Get the complete analysis for NSE:CLSL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CLSL has been successfully added to your 
